In this article, we will list the 5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now. Please visit 10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now if you would like to see the extended list and the methodology behind it.

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Short Float: 39.19%

Market Cap: $1.92 Billion

Stock Upside Potential: 53.97%

Number of hedge fund holders: 35

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, H.C. Wainwright reiterated Intellia Therapeutics (NASDAQ:NTLA) as a Buy but lowered the price target to $25 from $30. The price target cut is in response  to a recent share offering expected to result in significant dilution.

The company announced a $180 million follow-on equity offering of 16.7 million shares at $10.75 a share. The price offering represents an 18.6%  discount to the stock’s closing price following the announcement. While the offering was planned at $150 million, it was upsized to $180 million to generate more gross proceeds.

Amid the price target cut due to dilution concerns, H.C. Wainwright remains bullish with a Buy rating, impressed by Intellia Therapeutics’ top-line results in the Phase 3 lonvo-z trials, with 62% of patients turning out attack-free and therapy-free with no adverse events. The company is planning a regulatory submission for a potential first-half 2027 US launch.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage biotechnology company focused on developing potentially curative treatments using CRISPR/Cas9 gene editing technology. The company aims to permanently modify disease-causing genes in the human body through a single course of treatment.

4. Bob’s Discount Furniture Inc. (NYSE:BOBS)

Short Float: 22.44%

Market Cap: $1.72 Billion

Stock Upside Potential: 56.93%

Number of hedge fund holders: 35

Bob’s Discount Furniture Inc. (NYSE:BOBS) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 7, DA Davidson reiterated a Buy rating on Bob’s Discount Furniture Inc. (NYSE:BOBS)  but lowered the price target to $22 from $24.

The new price target, which comes after the company delivered better-than-expected quarterly results, is 10 times the furniture retailer’s 2027 EBITDA estimate. The research firm remains bullish about the company’s long-term outlook. The Buy rating is impressed by the push for share gains and growth in new markets.

DA Davidson has also touted merchandising initiatives at the back of a push for higher-end products. Omnichannel success and margin improvements also underscore improvements from early-year storm pressures. However, the research firm is still wary of risks that remain around housing conditions.

In the first quarter, Bob’s Discount Furniture achieved earnings per share of $0.09, in line with analyst expectations. As revenues increased 8.5% year over year to $578.1 million.

Bob’s Discount Furniture Inc. (NYSE:BOBS) is a large-scale American home furnishings retailer that operates over 200 showrooms across 27 U.S. states. The company sells affordable living room, bedroom, and dining room furniture, as well as mattresses and home decor.

3. ImmunityBio Inc. (NASDAQ:IBRX)

Short Float: 35.30%

Market Cap: $7.58 Billion

Stock Upside Potential:  79.39%

Number of hedge fund holders: 25

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics License Application (sBLA)  for ANKTIVA  Plus BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer.

The supplemental BLA was accepted for review based on additional scientific data that the company provided to the FDA. The data detailed overlapping features of papillary and CIS disease that pave the way for the expansion of the already approved indication of ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with papillary tumors.

At the International Society for Pharmacoeconomics and Outcomes Research 2026 conference, Immunitybio detailed the cost savings of ANTKIVA  in the treatment of non-muscle-invasive bladder cancer patients with carcinoma in situ. ANKTIVA plus BCG showed cost savings per cystectomy of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200. The cost savings resulted from lower drug acquisition and administration costs.

ImmunityBio Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing next-generation immunotherapies and cell therapies that activate a patient’s immune system to fight cancer and infectious diseases. Their goal is to stimulate both innate and adaptive immune systems to generate long-lasting immunological memory.

2. Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Short Float: 20.87%

Market Cap: $1.65 Billion

Stock Upside Potential: 91.22%

Number of hedge fund holders: 31

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, B Riley reiterated a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) with a $63 price target. The positive stance comes as the company enters into a pivotal stage in the potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy.

The company is staring at a potential FDA review of a Biologics License Application (BLA) and a PDUFA target set for August. The agency has already accepted the company’s Class 2 resubmission as complete. Capricor’s GMP manufacturing facility in San Diego has also completed an FDA Pre-License Inspection, with all Form 483 observations addressed. The facility is to support the initial commercial launch.

Manufacturing expansion is expected in the first half of 2027, up from the previous late 2027 timeline. Capricor also remains in a solid financial position to cover anticipated expenses and capital requirements through Q4 2027, excluding any potential revenue from product sales.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare and serious diseases. Their primary focus is treating Duchenne muscular dystrophy (DMD) through regenerative and anti-inflammatory medicine.

1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Short Float: 27.48%

Market Cap: $1.77 Billion

Stock Upside Potential: 123.43%

Number of hedge fund holders: 33

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 8, Chardan reiterated Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as a Buy but lowered its price target of the stock  to $14 from $16. The price target cut  is in response to Amtagvi’s launch guidance.

The company delivered solid first-quarter results driven by growth in the tumor-infiltrating lymphocyte (TIL) therapy Amtagvi. The company also reiterated that it is positioned for long-term revenue growth while advancing multiple ongoing and new clinical trials.

Revenue was up 45% year over year to $71 million, driven by accelerating Amtagvi adoption and a better cost structure. For the second quarter, Iovance Biotherapeutics expects revenue of between $86 million and $88 million, ahead of the street estimate of $84.36 million. Amtagvi’s revenue is expected to be between $79 million and $81 million.

For the full year, Iovance is projecting revenue of $350 million to $370 million, compared with $359.7 million that analysts expect. The full-year guidance underscores confidence in the company’s commercialization of Amtagvi amid strong demand.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biopharmaceutical company pioneering Tumor-Infiltrating Lymphocyte (TIL) therapies to treat solid tumor cancers. It harnesses the patient’s own immune system by extracting, expanding, and reinfusing these naturally occurring immune cells to recognize and destroy cancer cells.

READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.